| [1] |
Hart A，Gustafson SK，Skeans MA，et al.OPTN/SRTR 2015 Annual Data Report：Early effects of the new kidney allocation system[J].Am J Transplant，2017，17 Suppl 1：543-564.
|
| [2] |
Ferreiro JF，Morscio J，Dierickx D，et al.EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcrip-tomic features[J].Am J Transplant，2016，16（2）：414-425.
|
| [3] |
Kotton CN，Huprikar S，Kumar D.Transplant infectious diseases：a review of the scientific registry of transplant recipients published data[J].Am J Transplant，2017，17（6）：1439-1446.
|
| [4] |
Swerdlow SH，Campo E，Pileri SA，et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J].Blood，2016，127（20）：2375-2390.
|
| [5] |
Inayat F，Hassan GU，Tayyab GUN，et al.Post-transplantation lymphoproliferative disorder with gastrointestinal involvement[J].Ann Gastroenterol，2018，31（2）：248-251.
|
| [6] |
Dunn C，Nguyen HP，Patel V，et al.Primary cutaneous Hodgkinlike polymorphic post-transplant lymphoproliferative disorder[J].J Cutan Pathol，2019，46（5）：358-362.
|
| [7] |
Mouchli MA，Singh S，Loftus EV Jr，et al.Risk factors and outcomes of de novo cancers （excluding nonmelanoma skin cancer） after liver transplantation for primary sclerosing cholangitis[J].Transplantation，2017，101（8）：1859-1866.
|
| [8] |
Mahale P，Shiels MS，Lynch CF，et al.Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients[J].Am J Transplant，2018，18（2）：453-461.
|
| [11] |
Spagnoletti G，Salerno MP，Calia R，et al.Thymoglobuline plus basiliximab a mixed cocktail to start?[J].Transpl Immunol，2017，43-44：1-2.
|
| [9] |
Allen UD，Preiksaitis JK，AST Infectious Diseases Community of Practice.Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation[J].Am J Transplant，2013，13 Suppl 4：107-120.
|
| [10] |
AlDabbagh MA，Gitman MR，Kumar D，et al.The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients：a systematic review[J].Am J Transplant，2017，17（3）：770-781.
|
| [12] |
Martinez-Calle N，Alfonso A，Rifon J，et al.First-line use of rituximab correlates with increased overall survival in late posttransplant lymphoproliferative disorders：retrospective，single-centre study[J].Eur J Haematol，2017，98（1）：38-43.
|
| [13] |
Trappe RU，Dierickx D，Zimmermann H，et al.Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International，Prospective，Multicenter PhaseⅡTrial[J].J Clin Oncol，2017，35（5）：536-543.
|
| [14] |
Francis A，Johnson DW，Craig JC，et al.Incidence and predictors of cancer following kidney transplantation in childhood[J].Am J Transplant，2017，17（10）：2650-2658.
|
| [15] |
Eshraghian A，Imanieh MH，Dehghani SM，et al.Posttransplant lymphoproliferative disorder after liver transplantation：Incidence，long-term survival and impact of serum tacrolimus level[J].World J Gastroenterol，2017，23（7）：1224-1232.
|
